Home Apoptosis Bcl-2 inhibitor -Autophagy activator -Mitophagy activator -Apoptosis related activator ABT-737 仅限科研使用

ABT-737

ABT-737是一种BH3模拟抑制剂，作用于Bcl-xL，Bcl-2和Bcl-w，无细胞试验中EC50分别为78.7 nM，30.3 nM和197.8 nM；但对Mcl-1， Bcl-B及Bfl-1没有抑制作用。ABT-737可诱导线粒体通路的凋亡和线粒体自噬。Phase 2。

ABT-737 Chemical Structure

ABT-737 Chemical Structure

CAS: 852808-04-9

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1203.93 现货
5mg RMB 972.14 现货
50mg RMB 4659.22 现货
100mg RMB 7964.03 现货
1g RMB 23751 现货
更大包装 有超大折扣

400-668-6834

info@selleck.cn
免费分装
免费预溶

客户使用Selleck的ABT-737发表文献361篇

产品质控

批次： 纯度： 99.98%
99.98

ABT-737相关产品

相关信号通路图

Bcl-2 Signaling Pathways

Bcl-2信号通路图

Bcl-2抑制剂选择性比较

细胞实验数据示例

细胞系 实验类型 给药浓度 孵育时间 活性描述 文献信息
DMS53 Function assay 5 to 10 uM 12 hrs Inhibition of BCl-2/Bax interaction in human DMS53 cells harboring p53 mutant at 5 to 10 uM after 12 hrs by immunoprecipitation method 26982372
DMS53 Apoptosis assay 5 to 10 uM 12 hrs Induction of apoptosis in human DMS53 cells harboring p53 mutant assessed as caspase-3 cleavage at 5 to 10 uM after 12 hrs by immunoblotting method 26982372
DMS53 Apoptosis assay 5 to 10 uM 12 hrs Induction of apoptosis in human DMS53 cells harboring p53 mutant assessed as PARP cleavage at 5 to 10 uM after 12 hrs by immunoblotting method 26982372
DMS53 Function assay 5 to 10 uM 12 hrs Inhibition of BCl-2/Bim interaction in human DMS53 cells harboring p53 mutant at 5 to 10 uM after 12 hrs by immunoprecipitation method 26982372
DMS53 Apoptosis assay 5 to 10 uM 12 hrs Induction of apoptosis in human DMS53 cells harboring p53 mutant assessed as cytochrome c release at 5 to 10 uM after 12 hrs by immunoblotting method 26982372
RS4:11 Apoptosis assay 10 uM 24 hrs Induction of apoptosis in human RS4:11 cells at 10 uM incubated for 24 hrs by Annexin V and propidium iodide staining based FACS method 23047228
IM9 Apoptosis assay 10 uM 24 hrs Induction of apoptosis in human IM9 cells at 10 uM incubated for 24 hrs by Annexin V and propidium iodide staining based FACS method 23047228
BP3 Apoptosis assay 10 uM 24 hrs Induction of apoptosis in human BP3 cells at 10 uM incubated for 24 hrs by Annexin V and propidium iodide staining based FACS method 23047228
MDA-MB-231 Function assay 0.03 to 1 uM 1 hr Antagonist activity at recombinant Bcl-XL assessed as restoration of BIM BH3-induced cytochrome c release in mitochondria isolated from MDA-MB-231 cells at 0.03 to 1 uM after 1 hr by Western blot analysis 22747598
MDA-MB-231 Function assay 0.03 to 1 uM 1 hr Antagonist activity at recombinant Bcl-XL assessed as restoration of BIM BH3-induced Smac protein release in mitochondria isolated from MDA-MB-231 cells at 0.03 to 1 uM after 1 hr by Western blot analysis 22747598
HeLa Function assay 10 uM 16 hrs Inhibition of Rluc-Bax/eYFP-Bcl-xL interaction expressed in human HeLa cells at 10 uM after 16 hrs by BRET assay 22425031
HeLa Function assay 1 uM 12 hrs Induction of Bcl-xL-mediated apoptosis in doxycyclin-stimulated human HeLa cells overexpressing Noxa at 1 uM after 12 hrs by Hoechst staining 22386982
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 Y101H mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.38 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 F97V mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.3 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 L130G mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.29 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A142T mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.27 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 V141A mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.19 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 R100E mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.16 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 L130A mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.073 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 delta136T mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.06 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 L130V mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.058 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A142G mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.021 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A142Gdelta136T mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.01 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 E96G mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.0058 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 E129H mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.0045 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Wild type Bcl-2-like protein 1 expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.0034 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 Y195F mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.0015 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A93V mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.0014 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 G196A mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.001 μM. 21807512
RS4;11 Function Assay 100 nM 1/3/6 h induces caspase-dependent Mcl-1 cleavage 24951472
OPM-2  Apoptosis Assay 125/250/500 nM 48h  induces cell apoptosis in a dose-dependent manner 25008202
COG-LL-319 Function Assay 100 nM 1/3/6 h induces caspase-dependent Mcl-1 cleavage 24951472
RPMI-8226  Apoptosis Assay 125/250/500 nM 48h  induces cell apoptosis in a dose-dependent manner 25008202
OPM-2  Cell Viability Assay 125/250/500 nM 48h  decreases cell viability in a dose-dependent manner 25008202
RPMI-8226  Cell Viability Assay 125/250/500 nM 48h  decreases cell viability in a dose-dependent manner 25008202
Caco2 Apoptosis Assay 1/5/10 μM 48 h causes cell death in a dose-dependent manner 25192188
Colo205 Apoptosis Assay 1/5/10 μM 48 h causes cell death in a dose-dependent manner 25192188
SW480 Apoptosis Assay 1/5/10 μM 48 h causes cell death in a dose-dependent manner 25192188
HT29 Apoptosis Assay 1/5/10 μM 48 h causes cell death in a dose-dependent manner 25192188
CX-1 Growth Inhibition Assay 0.2–60 μM 72 h IC50=1.8 μM 25208882
LS174T Growth Inhibition Assay 0.2–60 μM 72 h IC50=18.3 μM 25208882
Clone A Growth Inhibition Assay 0.2–60 μM 72 h IC50=7.5 μM 25208882
MM.1S Function Assay 500/750 nM 24/48 h downregulates Bim, principally the EL isoform 25208888
U266 Function Assay 500/750 nM 24/48 h downregulates Bim, principally the EL isoform 25208888
RPMI8226 Function Assay 500/750 nM 24/48 h downregulates Bim, principally the EL isoform 25208888
A5-RT3 Function Assay 5 μM 6 h induces the release of mitochondrial proteins and reduces clonogenic survival in a caspase-independent manner 25210795
HaCaT Function Assay 10 μM 24/48 h induces MMP and DNA fragmentation 25210795
A5-RT3 Function Assay 10 μM 24/48 h induces MMP and DNA fragmentation 25210795
HaCaT Cell Viability Assay 0.1/1/10 μM 24 h decreases cell viability in a dose-dependent manner 25210795
A5-RT3 Cell Viability Assay 0.1/1/10 μM 24 h decreases cell viability in a dose-dependent manner 25210795
HCT116 Cell Viability Assay 0-10 μM 24 h  IC50=20.49 µM 25304383
LS411N Cell Viability Assay 0-10 μM 24 h  IC50=11.47 µM 25304383
SW620 Cell Viability Assay 0-10 μM 24 h  IC50=12.24 µM 25304383
Caco-2 Cell Viability Assay 0-10 μM 24 h  IC50=19.7 µM 25304383
DLD1 Cell Viability Assay 0-10 μM 24 h  IC50=18.78 µM 25304383
RL  Cell Viability Assay 0.0001-1 μM 96 h decreases the cell viability in a dose-dependent manner 25373508
RKO Cell Viability Assay 0-10 μM 24 h  IC50> 25 µM 25304383
OcI-LY18 Cell Viability Assay 0.0001-1 μM 96 h decreases the cell viability in a dose-dependent manner 25373508
H1299 Apoptosis Assay 20 μM 48 h induces apoptosis significantly combined with aspirin 25388762
Sc-1 Cell Viability Assay 0.0001-1 μM 96 h decreases the cell viability in a dose-dependent manner 25373508
A549 Apoptosis Assay 20 μM 48 h induces apoptosis significantly combined with aspirin 25388762
HT-29 Cell Viability Assay 0-20 μM 72 h decreases the cell survival in a dose-dependent manner combined with aspirin 25388762
HCT-116 Cell Viability Assay 0-20 μM 72 h decreases the cell survival in a dose-dependent manner combined with aspirin 25388762
HO-8910 Cell Viability Assay 0-20 μM 72 h decreases the cell survival in a dose-dependent manner combined with aspirin 25388762
H1299 Cell Viability Assay 0-20 μM 72 h decreases the cell survival in a dose-dependent manner combined with aspirin 25388762
ZR-75-1  Function Assay 5 μM 24 h enhances thelevel of Mcl-1 expression  25409124
A549 Cell Viability Assay 0-20 μM 72 h decreases the cell survival in a dose-dependent manner combined with aspirin 25388762
MCF-7 Function Assay 5 μM 24 h enhances thelevel of Mcl-1 expression  25409124
MDA-MB 231  Function Assay 5 μM 24 h enhances thelevel of Mcl-1 expression  25409124
MCF-7 Apoptosis Assay 5 μM 4/24/48 h increases the cleaved PARP 25409124
MCF-7 Cell Viability Assay 5 μM 48 h enhances the sensitivity to or radiation 25409124
K562 Cell Viability Assay 1-10 μM 48 h IC50=26.7 μM 25596561
U87 Function Assay 50 μM 24 h reduces the mRNA expression levels of MMP-2, MMP-14 and Bcl-2 25667663
HL-60 AAA-Bcl-2 Apoptosis Assay 0-5 μM 48 h IC50=0.87 μm，induces cell apoptosis in a dose-dependent manner 25711460
HL-60 EEE-Bcl-2 Apoptosis Assay 0-5 μM 48 h IC50=5 μm， induces cell apoptosis in a dose-dependent manner 25711460
U937  Apoptosis Assay 0.5 μM 24 h enhances cleavage of PARP and caspase-3 as well as Noxa level 25714024
U937 Apoptosis Assay 0.125-2 μM 24 h enhances DHA/X-11-induced apoptosis 25714024
HCT116 BAX BAK1 DKO Autophagy Assay 10 μM 12 h  induces a complete autophagic response 25715028
HCT116 BAX BAK1 DKO Function Assay 10 μM 12 h  increases GFP-LC3B puncta 25715028
HCT116 Autophagy Assay 10 μM 12 h  induces a complete autophagic response 25715028
HCT116 Function Assay 10 μM 12 h  increases GFP-LC3B puncta 25715028
HCT116 BAX BAK1 DKO Function Assay 3/10 μM 12 h  induces a dose-dependent increase in LC3B-II conversion and SQSTM1 degradation 25715028
HCT116 Function Assay 3/10 μM 12 h  induces a dose-dependent increase in LC3B-II conversion and SQSTM1 degradation 25715028
MM.1s Apoptosis Assay 0-1.6 μM 24 h induces cell apoptosis 25893290
MWCL-1 Apoptosis Assay 0-1.6 μM 24 h induces cell apoptosis 25893290
BCWM.1 Apoptosis Assay 0-1.6 μM 24 h induces cell apoptosis 25893290
B16 Cell Viability Assay 100 nM 72 h enhances curcumin-induced anti-survival  26116776
WM-115 Cell Viability Assay 100 nM 72 h enhances curcumin-induced anti-survival  26116776
LOUCY Growth Inhibition Assay 100-1000 nM 48 h IC50=32.8±10.9 nM 26172269
JURKAT Growth Inhibition Assay 100-1000 nM 48 h IC50=955±9.3 nM 26172269
CEM S Apoptosis Assay 10-1000 nM 24 h causes the cleavage of Bcl-2 and the downregulation of Bcl-xL and Mcl-1 26392332
MOLT-4 Apoptosis Assay 10-1000 nM 24 h causes the cleavage of Bcl-2 and the downregulation of Bcl-xL and Mcl-1 26392332
CEM S Growth Inhibition Assay 10-5000 nM 72 h IC50=12.1 μM 26392332
CEM R Growth Inhibition Assay 10-5000 nM 72 h IC50=5.4 μM 26392332
JURKAT Growth Inhibition Assay 10-5000 nM 72 h IC50=66 μM 26392332
RS4;11 Growth Inhibition Assay 10-5000 nM 72 h IC50=0.002 μM 26392332
MOLT-4 Growth Inhibition Assay 10-5000 nM 72 h IC50=0.198 μM 26392332
MC-3  Apoptosis Assay 5/10/20 μM 24 h induces caspase-mediated apoptosis 26447615
HN22  Apoptosis Assay 2.5/7.5/22.5 μM 24 h induces caspase-mediated apoptosis 26447615
HN22  Growth Inhibition Assay 2.5/7.5/22.5 μM 24 h inhibits cell growth in a dose-dependent manner 26447615
MC-3  Growth Inhibition Assay 5/10/20 μM 24 h inhibits cell growth in a dose-dependent manner 26447615
Kasumi-1 Apoptosis Assay 0-10 μM 24 h induces cell apoptosis in a dose-dependent manner 26552712
KG1a Apoptosis Assay 0-10 μM 24 h induces cell apoptosis in a dose-dependent manner 26552712
Kasumi-1 Cell Viability Assay 0-10 μM 24 h IC50=4.87 μM, decreases cell viability in a dose-dependent manner 26552712
KG1a Cell Viability Assay 0-10 μM 24 h IC50=7.68 μM, decreases cell viability in a dose-dependent manner 26552712
OCI-Ly1  Cell Viability Assay 250 nM  72 h caused 97% loss of viability in cells transfected with BCL6 siRNA 26657288
Eu-Myc Apoptosis assay 1 uM Induction of apoptosis in mouse Eu-Myc cells overexpressing BCL2 assessed as inhibition of colony formation at 1 uM 18040043
KB Cytotoxicity assay 0.5 uM Cytotoxicity in human siRNA-mediated-MCL1-kncok down KB cells overexpressing BCL2 at 0.5 uM 18040043
HCT116 Apoptosis assay 48 hrs Induction of apoptosis in human HCT116 p53+/+ cells after 48 hrs by Annexin V-FITC staining-based flow cytometric method 26982372
BL21 (DE3) Function assay 2 hrs Binding affinity to N-terminus 8X His-tagged human Bcl-xL expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay, Ki = 0.001 μM. 22448988
BL21 (DE3) Function assay 2 hrs Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay, Ki = 0.0006 μM. 22448988
Remb1 Cytotoxicity assay 24 hrs Cytotoxicity against human Remb1 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 1.4 μM. 29453135
RS4:11 Cytotoxicity assay 24 hrs Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 0.33 μM. 29453135
SKOV3 Growth inhibition assay 72 hrs Growth inhibition of human SKOV3 cells after 72 hrs by MTT assay, IC50 = 46.59 μM. 27712939
U266 Growth inhibition assay 72 hrs Growth inhibition of human U266 cells after 72 hrs by MTT assay, IC50 = 27.35 μM. 27712939
MCF7 Growth inhibition assay 72 hrs Growth inhibition of human MCF7 cells after 72 hrs by MTT assay, IC50 = 25.33 μM. 27712939
HL60 Growth inhibition assay 72 hrs Growth inhibition of human HL60 cells after 72 hrs by MTT assay, IC50 = 0.97 μM. 27712939
NCI-H1417 Cytotoxicity assay 4 days Cytotoxicity against human NCI-H1417 cells assessed as growth inhibition after 4 days by WST assay, IC50 = 0.1734 μM. 23448298
NCI-H187 Cytotoxicity assay 4 days Cytotoxicity against human NCI-H187 cells assessed as growth inhibition after 4 days by WST assay, IC50 = 0.1377 μM. 23448298
NCI-H1963 Cytotoxicity assay 4 days Cytotoxicity against human NCI-H1963 cells assessed as growth inhibition after 4 days by WST assay, IC50 = 0.054 μM. 23448298
K562 Apoptosis assay 48 hrs Induction of apoptosis in Mcl1 dependent human K562 cells after 48 hrs by Annexin V staining based flow cytometry, IC50 = 16.4 μM. 23314054
RS4:11 Apoptosis assay 48 hrs Induction of apoptosis in Bcl2 dependent human RS4:11 cells after 48 hrs by Annexin V staining based flow cytometry, IC50 = 0.27 μM. 23314054
NCI-H1417 Antiproliferative assay 4 days Antiproliferative activity against human NCI-H1417 cells after 4 days by WST8 assay, IC50 = 0.412 μM. 22747598
NCI-H1963 Antiproliferative assay 4 days Antiproliferative activity against human NCI-H1963 cells after 4 days by WST8 assay, IC50 = 0.059 μM. 22747598
NCI-H146 Antiproliferative assay 4 days Antiproliferative activity against human NCI-H146 cells after 4 days by WST8 assay, IC50 = 0.037 μM. 22747598
K562 Cytotoxicity assay 48 hrs Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay, IC50 = 34.7 μM. 22582991
HL60 Cytotoxicity assay 48 hrs Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay, IC50 = 0.76 μM. 22582991
CCRF-CEM Cytotoxicity assay 48 hrs Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay, IC50 = 0.74 μM. 22582991
NCI-H1417 Growth inhibition assay 4 days Growth inhibition of human NCI-H1417 cells after 4 days by WST8 assay, IC50 = 0.13 μM. 22448988
NCI-H146 Growth inhibition assay 4 days Growth inhibition of human NCI-H146 cells after 4 days by WST8 assay, IC50 = 0.097 μM. 22448988
BL21 (DE3) Function assay 2 hrs Binding affinity to N-terminus 8X His-tagged human Bcl-xL expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay, IC50 = 0.006 μM. 22448988
BL21 (DE3) Function assay 2 hrs Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay, IC50 = 0.002 μM. 22448988
HCT116 Cytotoxicity assay 72 hrs Cytotoxicity against human HCT116 cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay, IC50 = 47.7 μM. 22172701
DU145 Cytotoxicity assay 48 hrs Cytotoxicity against human DU145 cells after 48 hrs by cell titer-blue assay, IC50 = 27.6 μM. 19743858
MCF7 Cytotoxicity assay 48 hrs Cytotoxicity against human MCF7 cells after 48 hrs by cell titer-blue assay, IC50 = 21.26 μM. 19743858
Hepa-1c1c7 Cytotoxicity assay 48 hrs Cytotoxicity against mouse Hepa-1c1c7 cells after 48 hrs by cell titer-blue assay, IC50 = 8.68 μM. 19743858
H460 Cytotoxicity assay 48 hrs Cytotoxicity against human H460 cells after 48 hrs by cell titer-blue assay, IC50 = 8.03 μM. 19743858
SU-8686 Cytotoxicity assay 48 hrs Cytotoxicity against human SU-8686 cells after 48 hrs by cell titer-blue assay, IC50 = 4.24 μM. 19743858
HCT116 Cytotoxicity assay 48 hrs Cytotoxicity against human HCT116 cells after 48 hrs by cell titer-blue assay, IC50 = 4.06 μM. 19743858
Jurkat Cytotoxicity assay 48 hrs Cytotoxicity against human Jurkat cells after 48 hrs by cell titer-blue assay, IC50 = 1.38 μM. 19743858
MEF Cytotoxicity assay 24 hrs Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% fetal bovine serum, EC50 = 0.051 μM. 21366295
MEF Cytotoxicity assay 24 hrs Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% serum, EC50 = 0.051 μM. 21366295
MEF Cytotoxicity assay 24 hrs Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 1% serum, EC50 = 0.00203 μM. 21366295
NCI-H146 Cytotoxicity assay 48 hrs Cytotoxicity against human NCI-H146 cells assessed as cell viability after 48 hrs in presence of 10% human serum, EC50 = 0.087 μM. 18841882
FL5.12 Cytotoxicity assay 24 hrs Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl-XL assessed as cell viability after 24 hrs by MTS assay in absence of serum, EC50 = 0.03 μM. 18841882
FL5.12 Cytotoxicity assay 24 hrs Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl2 assessed as cell viability after 24 hrs by MTS assay in absence of serum, EC50 = 0.0077 μM. 18841882
UPCI:SCC90 Growth Inhibition Assay 72 h GI50=6.6 ± 1.5 μM 25139387
UD-SCC2 Growth Inhibition Assay 72 h GI50=28 ± 2.9 μM 25139387
93-VU-147T Growth Inhibition Assay 72 h GI50=4.3 ± 3.5 μM 25139387
UM-SCC47 Growth Inhibition Assay 72 h GI50=19 ± 12.3 μM 25139387
UM-SCC22B Growth Inhibition Assay 72 h GI50=19 ± 2.9 μM 25139387
PCI-15B Growth Inhibition Assay 72 h GI50=11 ± 4.5 μM 25139387
PCI-13 Growth Inhibition Assay 72 h GI50=15 ± 1.8 μM 25139387
OCI-AML3 Growth Inhibition Assay 72 h IC50 = 1950 nM 26045609
MOLM-13  Growth Inhibition Assay 72 h IC50 = 27.9 nM 26045609
HL-60  Growth Inhibition Assay 72 h IC50 = 10.7 nM 26045609
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells 29435139
Toledo Apoptosis assay Induction of apoptosis in human Toledo cells, LD50 = 0.06 μM. 24900652
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells 29435139
MOLT4 Antiproliferative assay Antiproliferative activity against human MOLT4 cells in presence of 10% human serum, EC50 = 0.622 μM. 28926247
RS4:11 Antiproliferative assay Antiproliferative activity against human RS4:11 cells in presence of 10% human serum, EC50 = 0.024 μM. 28926247
CLL Apoptosis assay Induction of apoptosis in human CLL cells, EC50 = 0.0045 μM. 20925433
SUDHL4 Growth inhibition assay Inhibition of cell growth in human SUDHL4 cells overexpressing Bcl2 in presence of 10% HS, EC50 = 0.85 μM. 17256834
FL5.12 Function assay Reversal of cytokine withdrawal protection in IL3 dependent Bcl-xL overexpressing mouse FL5.12 cells in presence of 3% FBS, EC50 = 0.22 μM. 17256834
SUDHL4 Growth inhibition assay Inhibition of cell growth in human SUDHL4 cells overexpressing Bcl2 in presence of 3% FBS, EC50 = 0.22 μM. 17256834
RS11380 Growth inhibition assay Inhibition of cell growth in human RS11380 cells overexpressing Bcl2 in presence of 10% HS, EC50 = 0.15 μM. 17256834
DoHH2 Growth inhibition assay Inhibition of cell growth in human DoHH2 cells overexpressing Bcl2 in presence of 10% HS, EC50 = 0.13 μM. 17256834
FL5.12 Function assay Reversal of cytokine withdrawal protection in IL3 dependent Bcl2 overexpressing mouse FL5.12 cells in presence of 3% FBS, EC50 = 0.05 μM. 17256834
FL5.12 Function assay Reversal of cytokine withdrawal protection in IL3 dependent Bcl-xL overexpressing mouse FL5.12 cells in presence of bovine gelatin, EC50 = 0.03 μM. 17256834
DoHH2 Growth inhibition assay Inhibition of cell growth in human DoHH2 cells overexpressing Bcl2 in presence of 3% FBS, EC50 = 0.0083 μM. 17256834
RS11380 Growth inhibition assay Inhibition of cell growth in human RS11380 cells overexpressing Bcl2 in presence of 3% FBS, EC50 = 0.014 μM. 17256834
FL5.12 Function assay Reversal of cytokine withdrawal protection in IL3 dependent Bcl2 overexpressing mouse FL5.12 cells in presence of bovine gelatin, EC50 = 0.008 μM. 17256834
U266 Growth Inhibition Assay IC50=0.68 μM 25535900
NCI-H929 Growth Inhibition Assay IC50=15.21 μM 25535900
MM.1S Growth Inhibition Assay IC50=0.40 μM 25535900
RPMI 8226 Growth Inhibition Assay IC50=0.25 μM 25535900
U937 Growth Inhibition Assay IC50=5.29 μM 25535900
C1498 Growth Inhibition Assay IC50=6.13 μM 25535900
THP-1 Growth Inhibition Assay IC50=1.27 μM 25535900
Kasumi-1 Growth Inhibition Assay IC50=0.01 μM 25535900
Kasumi-1/ABT Growth Inhibition Assay IC50=0.51 μM 25535900
JurkatΔBak Growth Inhibition Assay IC50>50 μM 25535900
HL60/VCR Growth Inhibition Assay IC50>100 μM 25535900
K562/Bcl- 2-IRESBim Growth Inhibition Assay IC50=0.35 μM 25535900
Jurkat Growth Inhibition Assay IC50=0.66 μM 25535900
K562/Mcl -1-IRESBim Growth Inhibition Assay IC50=9.3 μM 25535900
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells 29435139
点击查看更多细胞系数据

生物活性

产品描述 ABT-737是一种BH3模拟抑制剂，作用于Bcl-xL，Bcl-2和Bcl-w，无细胞试验中EC50分别为78.7 nM，30.3 nM和197.8 nM；但对Mcl-1， Bcl-B及Bfl-1没有抑制作用。ABT-737可诱导线粒体通路的凋亡和线粒体自噬。Phase 2。
特性 ABT-737是第一代抗凋亡BCL-2家族蛋白小分子抑制剂。
靶点
Bcl-2 [1]
(Cell-free assay)		 Bcl-xL [1]
(Cell-free assay)		 Bcl-w [1]
(Cell-free assay)		 Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
体外研究(In Vitro)
体外研究活性 ABT-737降低BCL-2/BAX异质二聚体,而诱导HL60细胞凋亡,但是对细胞周期分布没有抑制效果。ABT-737也诱导细胞色素C从线粒体中释放，促进BAX构象改变，BAX与凋亡相关。在白血病模型中，ABT-737按30 mg/kg处理，阻断53%白血病负荷，且使鼠寿命明显延长。ABT-737不会导致血细胞数和血清组成发生异常。[1]通过使Mcl-1失活而使抵抗细胞（Hela和MCF-7）对ABT-737敏感。当Mcl-1无效时，ABT-737也导致BAX/BAK-依赖的细胞色素C释放。ABT-737延长携带BCL-2肿瘤的鼠寿命。[2]ABT-737从BCL2’s BH3结合袋取代BIM,使BIM激活BAX,诱导线粒体透化作用,快速致死慢性淋巴细胞性白血病(CLL)细胞。[3] Noxa正向调节增强H196细胞对ABT-737敏感性。ABT-737抑制多种SCLC细胞系，包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146等的增殖，并诱导细胞凋亡。最近研究显示，ABT-737作用于ATLL细胞，明显诱导HTLV-1感染的T细胞凋亡。ABT-737按100 mg/kg剂量作用于ATLL鼠模型显示出强抗癌活性。[5]
激酶实验 荧光偏振实验
测定GST-BCL-2蛋白家族与FITC-BIM BH3域结合的亲和力。100 nM GST-BCL-2家族融合蛋白和不同浓度 ABT-737在PBS温育2分钟。然后，加入20 nM FITC-BIM BH3 肽。进行荧光偏振，测定IC50值。
细胞实验 细胞系 SCLC细胞系，包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR,和DMS114
浓度 0.001-10 μM
孵育时间 48小时
方法

SCLC细胞在含10%人血浆的 100 μL 组织培养基的96孔培养板上处理48小时，使用MTS测定存活细胞。
实验图片 检测方法 检测指标 实验图片 PMID
Western blot PARP / c-PARP / cleaved caspase 3 Hif-1a γ-H2AX / p-ATM 21393866
Immunofluorescence cytochrome C Bax Bim AIF p65 26447615
Growth inhibition assay Cell viability 22311987
ELISA IL-6 / IL-8 21084274
体内研究(In Vivo)
体内研究活性 ABT-737按30 mg/kg剂量作用于白血病模型，抑制白血病负担值达53% , 且明显延长鼠寿命。ABT-737不会引起血细胞数和血浆化学性质发生变话。[1] ABT-737延长移植BCL-2传感肿瘤的鼠寿命。[2] ABT-737按100 mg/kg剂量作用于ATLL鼠模型具有强抗癌活性。[5]
动物实验 Animal Models 注射ER细胞的Scid 鼠
Dosages 20 mg/kg和30 mg/kg
Administration 腹腔注射

化学信息&溶解度

分子量 813.43 分子式

C42H45ClN6O5S2
CAS号 852808-04-9 SDF Download ABT-737 SDF
Smiles CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]
储存条件(自收到货起)

体外溶解度
批次：

DMSO : 100 mg/mL ( (122.93 mM)； DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

 动物体内配方计算器

实验计算

摩尔浓度计算器

质量 浓度 体积 分子量

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

mg/kg g μL 只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
What’s the recommended method about reconstitution of the compound for in vivo animal study?

回答：
For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
在线咨询
联系我们